Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

New twists on proteasome inhibitors

Nature Biotechnology volume 28, pages 1236–1238 (2010)Cite this article

Subjects

Only one drug targeting the proteasome protein degradation pathway has been approved, but several second-generation inhibitors are making progress in trials. Jim Kling reports.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The pyramidal ubiquitin cascade.

References

  1. Adams, J. Cancer Cell 5, 417–421 (2004).

    Article  CAS  Google Scholar 

  2. Rumpold, H. Biochem. Biophys. Res. Commun. 361, 549–554 (2007).

    Article  CAS  Google Scholar 

  3. Orlicky, S. et al. Nat. Biotechnol. 28, 733–737 (2010).

    Article  CAS  Google Scholar 

  4. Levine, S. et al. N. Engl. J. Med. 358, 1327–1335 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bellingham, Washington

    Jim Kling

Authors
  1. Jim Kling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kling, J. New twists on proteasome inhibitors. Nat Biotechnol 28, 1236–1238 (2010). https://doi.org/10.1038/nbt.1727

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1727

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer